Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has required the urgent development of new therapies, among which passive immunotherapy is contemplated. CoviFab (INM005) is a RBD-specific F(ab′)2 fragment derived from equine polyclonal antibodies. We investigate their preclinical se...

Descripción completa

Detalles Bibliográficos
Autores principales: Salinas, Facundo, Marelli, Belkis E., Sanguineti, Santiago, Goldbaum, Fernando, Muñoz, Luciana, Etchevers, Lucas, Silvestrini, Paula, Notaro, Ulises S., Salvetti, Natalia R., Zylberman, Vanesa, Ortega, Hugo H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590615/
https://www.ncbi.nlm.nih.gov/pubmed/34785274
http://dx.doi.org/10.1016/j.taap.2021.115796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590615/
https://www.ncbi.nlm.nih.gov/pubmed/34785274
http://dx.doi.org/10.1016/j.taap.2021.115796

Ejemplares similares